Cancer pharmacogenetics

Methods in Molecular Biology

Volumn 448, Issue , 2008, Pages 437-446

  Marsh, Sharon ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Genotyping; Germline; Mutation; Polymorphism; Tumor

Indexed keywords

EID: 84934439748     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-205-2_15     Document Type: Article

References (38)

1. Evans, W. E., and McLeod H. L. (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 348, 538-549.
2. Pui, C. H., and Evans, W. E. (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med. 354, 166-178.
3. Relling, M. V., Hancock, M. L., Boyett, J. M., Pui, C. H., and Evans, W. E. (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 93, 2817-2823.
4. McLeod, H. L., and Siva, C. (2002) The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics. 3, 89-98.
5. Relling, M. V., Hancock, M. L., Rivera, G. K., et al. (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 91, 2001-2008.
6. Beutler E., Gelbart T., and Demina A. (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 95, 8170-8174.
7. Innocenti, F., and Ratain, M. J. (2004) "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 75, 495-500.
8. Ratain, M. J. (2006) From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res. 12, 1658-1660.
9. FDA clears Third Wave pharmacogenetic test. Pharmacogenomics. 6, 671-672 (2005).
10. Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar). Med Lett Drugs Ther. 48, 39-40 (2006).
11. Fukuoka, M., Yano, S., Giaccone, G., et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 21, 2237-2246.
12. Cohen, M. H., Williams, G. A., Sridhara, R., et al. (2004) United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 10, 1212-1218.
13. Paez, J. G., Janne, P. A., Lee, J. C., et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304, 1497-1500.
14. Lynch, T. J., Bell, D. W., Sordella, R., et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350, 2129-2139.
15. Pao, W., Miller, V. A., Politi, K. A., et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73.
16. Meucci, M. A., Marsh, S., Watters, J. W., and McLeod, H. L. (2005) CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics. 6, 59-63.
17. Feng, W. H., Hong, G., Delecluse, H. J., and Kenney, S. C. (2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 78, 1893-1902.
18. Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1997) Genetic instability in colorectal cancers. Nature. 386, 623-627.
19. Lenz, H. J. (2004) The use and development of germline polymorphisms in clinical oncology. J Clin Oncol. 22, 2519-2521.
20. Savage, S. A., and Chanock, S. J. (2004) Using germ-line genetic variation to investigate and treat cancer. Drug Discov Today. 9, 610-618.
21. Marsh S., Mallon M. A., Goodfellow P., and McLeod H. L. (2005) Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics. 6, 873-877.
22. Hoskins, J. M., and Mcleod, H. L. (2006) Cancer pharmacogenetics: the move from pharmacokinetics to pharmacodynamics. Current Pharmacogenomics. 4, 39-46.
23. Rylander-Rudqvist, T., Hakansson, N., Tybring, G., and Wolk, A. (2006) Quality and quantity of saliva DNA obtained from the self-administrated oragene method-a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev. 15, 1742-1745.
24. McLeod, H. L., and Marsh, S. (2005) Pharmacogenetics goes 3D. Nat Genet. 37, 794-795.
25. Kidd, E. A., Yu, J., Li, X., Shannon, W. D., Watson, M. A., and McLeod, H. L. (2005) Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res. 11, 2612-2619.
26. Yu, J., Shannon, W. D., Watson, M. A., and McLeod, H. L. (2005) Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res. 11, 2053-2062.
27. Widschwendter, A., Muller, H. M., Fiegl, H., et al. (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res. 10, 565-571.
28. Taback, B., Giuliano, A. E., Lai, R., et al. (2006) Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann N Y Acad Sci. 1075, 211-221.
29. McLeod, H. L. (2004) Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics. 5, 139-141.
30. Freimuth, R. R., Ameyaw, M.-M., Pritchard, S. C., Kwok, P.-Y., and McLeod, H. L. (2004) Highthroughput genotyping methods for pharmacogenomic studies. Current Pharmacogenomics. 2, 21-33.
31. Kwok, P. Y. (2001) Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet. 2, 235-258.
32. Syvanen, A. C. (2005) Toward genome-wide SNP genotyping. Nat Genet. 37 S, S5-S10.
33. Innocenti, F. Pharmacogenomics: methods and protocols. Totowa, NJ: Humana Press; 2005.
34. Van Booven, D. J. (2006) Pyrosequencing genotype storage techniques. Methods Mol Biol. 373, 177-186.
35. McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., and Clark, G. M. (2005) Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer. 93, 387-391.
36. Benjamini, Y., and Hochberg, Y. (1995) Controlling false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc Br. 57, 289-300.
37. Rae, J. M., Cordero, K. E., Scheys, J. O., Lippman, M. E., Flockhart, D. A., and Johnson, M. D. (2003) Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics. 13, 501-507.
38. Engen, R. M., Marsh, S., Van Booven, D. J., and McLeod, H. L. (2006) Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets. 7, 1641-1648.